News | Heart Valve Technology | September 06, 2018

Gore Acquires Pipeline Medical Technologies Inc.

Acquisition of transcatheter mitral chordal repair technology builds on Gore’s structural heart capabilities

Gore Acquires Pipeline Medical Technologies Inc.

September 6, 2018 – W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately held medical technology company focused on advancing chordal repair for degenerative mitral regurgitation (DMR) via a transcatheter procedure.

The Pipeline device is designed to replicate the outcomes of a highly effective surgical procedure via a catheter, avoiding the trauma and many of the risks associated with open heart surgery. “An entirely catheter-based, transfemoral and transseptal chordal repair will be an important tool for minimally invasive treatment of mitral regurgitation,” commented Paul Sorajja, M.D., director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital.

“We see an array of synergies working with Gore. The company is well recognized for its advanced material capabilities. Its long history of designing solutions for DMR treatment challenges already includes the Gore-Tex Suture for Chordae Tendineae, used in surgical chordal repairs and we are excited to collaborate on future innovations in transcatheter mitral chordal repair,” said Pipeline founder Steven Bolling, M.D., a leading mitral valve surgeon. “Together we aspire to significantly advance DMR patient outcomes and improve recovery speed.”

The company will retain the Pipeline name and operate independently of Gore as a wholly owned subsidiary. Pipeline’s device is currently in development and not available for commercial use.

For more information: www.gore.com

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init